In patients with chronic kidney disease (CKD), there is an increased incidence of low bone mass and fractures and coronary artery calcification and cardiovascular mortality compared to the general population. This syndrome of interrelated bone disease, extraskeletal calcification, and disordered mineral metabolism is called Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD). However, the mechanism by which these important clinical manifestations are inter-related remains unknown. Bisphosphonates are effective in preventing fractures in multiple non-CKD bone diseases, and can also improve arterial calcification in animal models. Newer bisphosphonates such as zoledronic acid also inhibit angiogenesis through down regulation of vascular endothelial growth factor (VEGF). VEGF levels are elevated in CKD patients and associated with increased mortality. VEGF is also critical for normal bone remodeling. Zoledronic acid, by improving both bone remodeling and VEGF expression in bone and vasculature, may correct the abnormalities of CKD-MBD. Thus, our hypothesis is that CKD induces bone and cardiac disease in CKD (CKD-MBD) through activation of VEGF and this can be inhibited with zoledronic acid. To test this hypothesis we will use the Cy/+ (CKD) rat, a novel animal model of CKD that develops a naturally-occurring, slowly-progressive CKD-MBD with hyperphosphatemia and secondary hyperparathyroidism, increased bone remodeling and bone loss, arterial calcification, and left ventricular hypertrophy, accurately reflecting the clinical disease progression observed in humans with CKD.
In Aim 1, after initial efficacy and toxicity studies, we will determine the efficacy of zoledronic acid on the prevention and treatment of the bone and cardiovascular abnormalities of CKD-MBD by treating CKD and normal rats with zoledronic acid at early and late time points and determine the effect of serum measures of mineral homeostasis, bone turnover, architecture and biomechanics, and arterial calcification, aorta compliance and left ventricular mass index.
In Aim 2, we will determine if CKD increases VEGF expression in bone and vascular tissue and if this can be blocked with zoledronic acid through a series of ex vivo and in vitro experiments. Lastly, in Aim 3, we will determine the effect of VEGF inhibition in vivo on the bone and cardiovascular abnormalities of CKD-MBD in conditions of extremes of bone remodeling by treating CKD animals with high turnover bone disease, or low turnover bone disease induced by increased calcium intake, with an anti-VEGF antibody (bevacizumab) or zoledronic acid in a 2 x 2 design, and biochemical, skeletal, and vascular parameters similar to Aim 1 determined. These studies will utilize a novel animal model of slowly progressive CKD-MBD to test the innovative hypothesis that VEGF is a key mechanistic player in the pathogenesis of CKD-MBD. Given that 1 in 9 individuals in the U.S. have CKD stages 3-5 with increased fractures and cardiovascular disease from CKD-MBD, this has important public health implications.

Public Health Relevance

In patients with chronic kidney disease there is abnormal bone and hardening of the arteries. Both of these problems may be linked. The purpose of this study is to determine if a commonly used group of drugs, bisphosphonates, may help both bone and heart/blood vessel disease and determine the mechanism the drugs work.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Research Project (R01)
Project #
Application #
Study Section
Skeletal Biology Development and Disease Study Section (SBDD)
Program Officer
Sharrock, William J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Moe, Sharon M; Chen, Neal X; Newman, Christopher L et al. (2015) Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res 30:499-509
Chen, Neal X; O'Neill, Kalisha; Akl, Nader Kassis et al. (2014) Adipocyte induced arterial calcification is prevented with sodium thiosulfate. Biochem Biophys Res Commun 449:151-6
Reilly, Austin M; Gray, Amie K; Moe, Sharon M et al. (2014) Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium. Bone 67:139-44
Moe, Sharon M; Chen, Neal X; Newman, Christopher L et al. (2014) A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res 29:902-10
Newman, Christopher L; Moe, Sharon M; Chen, Neal X et al. (2014) Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease. PLoS One 9:e99262
Chen, Neal X; Kiattisunthorn, Kraiwiporn; O'Neill, Kalisha D et al. (2013) Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD). PLoS One 8:e64558
Allen, Matthew R; Chen, Neal X; Gattone 2nd, Vincent H et al. (2013) Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment. Am J Nephrol 38:458-64
Sprague, Stuart M; Moe, Sharon M (2013) The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol 8:313-8
Moorthi, Ranjani N; Moe, Sharon M (2013) Recent advances in the noninvasive diagnosis of renal osteodystrophy. Kidney Int 84:886-94
Sprague, Stuart M; Moe, Sharon M (2013) Rebuttal: PTH--a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol 8:321

Showing the most recent 10 out of 12 publications